JAN 15, 2016 04:00 AM PST

Multiplex IHC and novel monoclonal antibodies as enabling tools for the study of tumor immunology

  • Principal Scientist, Translational Assays, Cell Signaling Technology
      Matthew Silver leads the Translational Assays Group at Cell Signaling Technology, Inc. where he focuses on the development of both translational research reagents and multiplex assays. Matthew received his PhD in Biochemistry from the University of New Hampshire where he studied the neuroendocrine regulation of reproduction. His subsequent postdoctoral studies were performed at Wyeth Research within the Department of Inflammation.

    DATE: January 15, 2016
    TIME: 7am EST, 12pm UK, 1pm CET

    With an increasing number of biomarkers and, often, limited availability of biopsy material, there is a growing need for multiplexed assays for both research and clinical purposes.  IHC based solutions are particularly attractive in the field of immuno-oncology, as maintaining spatial context within the tumor microenvironment provides meaningful and potentially actionable information.  Immuno-assays with high specificity and sensitivity are a powerful tool, however, there are challenges associated with antibody based multiplexing, particularly when the analysis involves greater than 2-3 markers.  Multiplex IHC is a method that bypasses antibody species/isotype concerns, while providing signal amplification, and was thus used to examine the co-expression of immune checkpoint control proteins, such as PD-L1, B7-H4, and VISTA, in breast and ovarian cancer tissue samples. 
    Target Audience
    This webinar will be ideal for academic and pharmaceutical researchers who are interested in exploiting fluorescence immunohistochemistry as a multiplex assay to investigate the interplay and spatial orientation of multiple proteins of interest in the context of three-dimensional tissue architecture.

    Show Resources
    Loading Comments...